

### COVID-19 IMPACT

This report has been affected by the COVID-19 pandemic. All forecasts and analysis have been revised to reflect the current view including the effect of the pandemic and associated recession.

# RESEARCH REPORT



## Genetic Testing.

Global Market Forecasts for Applications and Technologies.

**Updated for COVID-19 Pandemic impact**

With Executive and Consultant Guides

2021 to 2025



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the X-Ray market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

## Table of Contents

i. Genetic Testing - Strategic Situation Analysis & Impact of COVID-19 Pandemic .....	21
ii. Guide for Executives, Marketing, Sales and Business Development Staff .....	23
iii. Guide for Management Consultants and Investment Advisors .....	25
1. Introduction and Market Definition .....	27
1.1 Genetic Testing Definition in This Report .....	28
1.2 The Genomics Revolution .....	29
1.3 Market Definition .....	31
1.3.1 Revenue Market Size.....	31
1.3.1 Newborn Screening .....	32
1.3.2 Non Invasise Pregnancy Testing.....	32
1.3.3 Predictive .....	32
1.3.4 Oncology .....	32
1.3.5 Direct to Consumer .....	32
1.3.6 Other Application.....	32
1.3.7 PCR .....	33
1.3.4 NGS.....	33
1.3.5 Cytogenetic.....	33
1.3.6 Other Technology .....	33
1.4 U.S. Medical Market and laboratory Testing - Perspective .....	34
1.4.1 U.S. Medicare Expenditures for Laboratory Testing .....	35
2. Market Overview .....	37

- 2.1 Market Participants Play Different Roles ..... 38
  - 2.1.1 Supplier/pharmaceutical ..... 39
  - 2.1.2 Independent lab specialized/esoteric ..... 39
  - 2.1.3 Independent lab national/regional..... 39
  - 2.1.4 Independent lab analytical ..... 40
  - 2.1.5 Public National/regional lab ..... 40
  - 2.1.6 Hospital lab ..... 40
  - 2.1.7 Physician lab ..... 41
  - 2.1.8 DTC Lab..... 41
  - 2.1.9 Independent Genetic Testing Lab..... 41
  - 2.1.10 Audit Body..... 42
- 2.2 Genetic Tests –Types, Examples and Discussion ..... 43
  - 2.2.1 Preimplantation Genetic Diagnosis- An Emerging Market ..... 43
  - 2.2.2 Prenatal Diagnosis – New Technologies Create Opportunity ..... 44
  - 2.2.3 Newborn Screening ..... 44
  - 2.2.2 Diagnostic Testing ..... 45
  - 2.2.3 Carrier Testing ..... 45
  - 2.2.6 Predictive and Presymptomatic Testing..... 46
  - 2.2.7 Pharmacogenomics ..... 46
  - 2.2.8 Forensic Testing..... 47
  - 2.2.9 Parental Testing ..... 47
  - 2.2.10 Ancestral Testing..... 47
- 2.3 Industry Structure ..... 49
  - 2.3.1 Hospital's Testing Share ..... 49

- 2.3.2 Economies of Scale ..... 49
  - 2.3.2.1 Hospital vs. Central Lab ..... 50
- 2.3.3 Physician Office Lab's ..... 51
- 2.3.4 Physician's and POCT ..... 51
- 2.4 Market Shares of Key Genetics Players - Analysis ..... 52
- 3. Market Trends.....53
  - 3.1 Factors Driving Growth..... 54
    - 3.1.1 Genetic Discoveries Creating New Diagnostic Markets ..... 54
    - 3.1.2 Aging Population a Boon for Diagnostics..... 55
    - 3.1.3 Pharmacogenomics Drives Further Growth. .... 56
    - 3.1.4 Oncology and Liquid Biopsy Enter New Era ..... 56
    - 3.1.5 Fertility Practice Growth drives market ..... 57
    - 3.1.6 Direct to Consumer begins to break out ..... 57
  - 3.2 Factors Limiting Growth..... 58
    - 3.2.1 Increased Competition Lowers Price ..... 58
    - 3.2.2 Lower Costs..... 59
    - 3.2.3 Testing usage analysis curtailing growth. .... 59
    - 3.2.4 Wellness has a downside ..... 59
  - 3.3 Instrumentation and Automation..... 61
    - 3.3.1 Instruments Key to Market Share ..... 61
    - 3.3.2 Bioinformatics Plays a Role. .... 61
  - 3.4 Diagnostic Technology Development ..... 62
    - 3.4.1 Next Generation Sequencing Fuels a Revolution..... 63
    - 3.4.2 Impact of NGS on pricing..... 64

3.4.3 POCT/Self Testing Disruptive Force..... 64

3.4.4 Pharmacogenomics Blurs Diagnosis and Treatment..... 65

3.4.5 CGES Testing, A Brave New World ..... 66

3.4.6 Biochips/Giant magneto resistance based assay..... 66

4. Genetic Testing Recent Developments.....68

4.1.1 Importance of This Section ..... 68

4.1.2 How to Use This Section..... 68

Progenity Revenues Fall on COVID-19 Effect..... 68

Natera Launches Tumor Genomic Profiling Assay..... 70

23andMe To Go Public ..... 73

Guardant Health to Offer Tumor Tissue Sequencing ..... 74

Ancestry Quits Health Offering..... 77

DTC Firm MyDNA Merges With Gene by Gene..... 82

Aetna Coverage for NIPT to Include All Pregnancies ..... 82

Agios Pharmaceuticals, PerkinElmer Partner on Hereditary Anemia Genetic Testing ..... 83

Tumor, Germline Testing of Cancer Patients Can Give Discordant Results ..... 84

Invitae Completes Acquisition of ArcherDx ..... 86

Prenetics Receives \$15M Investment..... 87

Sanford Health Invests \$800K in TruGenomix as Part of PTSD Test Alliance ..... 88

Preconception Carrier Screening Trial Begins in Australia..... 88

Genetic Testing Clinical Use Just Beginning ..... 89

Fulgent Genetics Q1 Revenues Jump 44 Percent ..... 91

Blueprint Genetics, NICER Consortium Developing Genetic Test for Immunologic,  
Hematologic Disorders..... 92

Natera Terminates Qiagen Agreement for Developing NGS-Based Genetic Tests ..... 93

Invitae Acquires Three Companies: YouScript, Genelex, Diploid..... 94

PerkinElmer SCID Test Chosen for Newborn Screening Evaluation in England ..... 96

Germline Cancer Risk Mutations Sometimes Reported in Tumor Testing ..... 97

Blueprint Genetics, Archimedlife to Launch Genetic Testing in North America ..... 105

Invitae to Offer No-Charge Genetic Testing to Pancreatic Cancer Patients ..... 105

Phosphorus Offers DNA Testing to Assess Disease Risk..... 107

Arivale Shuts Down Personalized Wellness Business ..... 108

ArcherDX Acquires Baby Genes ..... 109

MDxHealth, LifeLabs Ink Distribution Agreement for Prostate Cancer Assay ..... 110

Thermo Fisher Purchases 9 Percent Stake in Yourgene Health ..... 111

Invitae Partners to Expand Free Epilepsy Genetic Testing Program..... 112

Illumina, Chinese Firm Partner on NGS System for Genetic Disease Dx ..... 113

NanoString Technologies Prices \$103.5M Common Stock Offering ..... 114

Canine Consumer Genomics Firm Embark Veterinary Raises \$10M ..... 115

Yourgene Health to Acquire Elucigene..... 115

Helix, AdventHealth Partner on Genetic Screening Study ..... 116

5. Profiles of Key Companies ..... 118

    10x Genomics, Inc..... 119

    23andME Inc..... 120

    Abbott Diagnostics ..... 122

    AccuraGen Inc. .... 124

    Adaptive Biotechnologies ..... 125

    Admera Health, LLC..... 126



Agena Bioscience, Inc.....	127
Agilent.....	129
Akoni Biosystems.....	131
Ancestry.com LLC.....	132
Anchor Dx.....	134
ArcherDx, Inc.....	135
ARUP Laboratories.....	136
Asuragen.....	138
Baylor Miraca Genetics Laboratories.....	140
Beckman Coulter, Inc.....	141
Becton, Dickinson and Company.....	143
BGI Genomics Co. Ltd.....	145
Bioarray Genetics.....	147
Biocept, Inc.....	148
Biodesix Inc.....	149
BioFluidica.....	150
BioGenex.....	151
Biolidics Ltd.....	153
bioMérieux Diagnostics.....	154
Bioneer Corporation.....	156
Bio-Rad Laboratories, Inc.....	158
Bio-Techne.....	160
Cancer Genetics.....	162
Caris Molecular Diagnostics.....	164

CellMax Life ..... 165

Centogene ..... 166

Chronix Biomedical ..... 170

Circulogene ..... 171

Clinical Genomics ..... 172

Color Genomics ..... 173

Complete Genomics, Inc. – A BGI Company ..... 174

Cynvenio ..... 176

Dante Labs ..... 177

Datar Cancer Genetics Limited ..... 179

Diasorin S.p.A. .... 180

Epic Sciences ..... 181

Epigenomics AG ..... 182

Eurofins Scientific ..... 183

Excellerate Bioscience ..... 186

Exosome Diagnostics ..... 187

Fabric Genomics ..... 189

Fluidigm Corp ..... 190

Foundation Medicine ..... 192

Freenome ..... 193

FUJIFILM Wako Diagnostics ..... 194

Fujirebio ..... 195

GE Global Research ..... 196

GE Healthcare Life Sciences ..... 198

Gene by Gene, Ltd..... 200

Genedrive..... 202

GeneFirst Ltd..... 203

Genetron Health (Beijing) Co., Ltd. .... 204

Genewiz..... 205

Genomic Health..... 206

Genomics England ..... 208

Genomics Personalized Health (GPH) ..... 210

GenomOncology..... 212

Genzyme Corporation..... 213

Grail, Inc..... 215

Grifols..... 217

Guardant Health..... 218

Guardiome ..... 219

HeiScreen..... 221

Helix ..... 222

Helomics..... 224

Hologic ..... 225

Horizon Discovery ..... 227

HTG Molecular Diagnostics ..... 229

Human Longevity, Inc..... 231

iCellate..... 233

Illumina ..... 234

Incell Dx..... 235

Inivata .....	236
Integrated Diagnostics .....	237
Invitae Corporation.....	238
Invivoscribe .....	240
Karius .....	241
Macrogen.....	242
MDNA Life SCIENCES, Inc.....	243
MDx Health .....	244
Medgenome .....	245
Meridian Bioscience.....	246
Mesa Biotech.....	248
MIODx.....	249
miR Scientific.....	250
MNG Labs .....	251
Molecular MD .....	252
NantHealth, Inc. ....	253
Natera .....	255
Nebula Genomics.....	257
NeoGenomics .....	258
New Oncology .....	260
Novogene Bioinformatics Technology Co., Ltd.....	261
Omega Bioservices .....	263
OncoDNA .....	265
ORIG3N, Inc. ....	266

Origene Technologies.....	268
Oxford Nanopore Technologies .....	269
Pacific Biosciences.....	272
Panagene .....	273
Perkin Elmer.....	274
Personal Genome Diagnostics.....	276
Personalis .....	277
Precipio .....	278
PrecisionMed .....	279
Promega .....	280
Protagen Diagnostics.....	282
Qiagen Gmbh .....	283
Quantumdx .....	286
Regeneron.....	287
Roche Molecular Diagnostics .....	289
Roswell Biotechnologies .....	291
Seegene .....	292
Sequencing.com.....	294
Siemens Healthineers .....	296
simfo GmbH .....	298
Singlera Genomics Inc.....	299
SkylineDx .....	300
Stratos Genomics .....	301
Sure Genomics, Inc. ....	302

Sysmex..... 304  
 Sysmex Inostics ..... 305  
 Tempus Labs, Inc..... 307  
 Thermo Fisher Scientific Inc..... 308  
 Veritas Genetics ..... 310  
 Volition ..... 312  
 6. Global Market Size.....313  
 6.1 Global Market by Country ..... 314  
     6.1.1 Table – Global Market by Country..... 314  
     6.1.2 Chart – Country Market Shares ..... 315  
 6.2 Global Market by Application..... 316  
     6.2.1 Table – Global Market by Application ..... 316  
     6.2.2 Chart – Application Share by Year ..... 317  
     6.2.3 Chart – Application Segment Growth Rates ..... 318  
     6.2.4 Chart – Application Segment Share Shifts..... 319  
     6.2.5 Chart – Application Segment Share Base Year ..... 320  
     6.2.6 Chart – Application Segment Share Final Year ..... 321  
 6.3 Global Market by Technology..... 322  
     6.3.1 Table – Global Market by Technology ..... 322  
     6.3.2 Chart – Technology Share by Year ..... 323  
     6.3.3 Chart – Technology Segment Growth Rates ..... 324  
     6.3.4 Chart – Technology Segment Share Shifts..... 325  
     6.3.5 Chart – Technology Segment Share Base Year ..... 326  
     6.3.6 Chart – Technology Segment Share Final Year ..... 327

7. Market Sizes by Application.....328

7.1 Newborn Testing Market ..... 329

7.1.1 Table Newborn – by Country..... 329

7.1.2 Chart – Newborn Growth ..... 330

7.2 NIPT Market ..... 331

7.2.1 Table NIPT – by Country ..... 331

7.2.2 Chart – NIPT Growth ..... 332

7.3 Predictive Testing Market ..... 333

7.3.1 Table Predictive – by Country ..... 333

7.3.2 Chart – Predictive Growth ..... 334

7.4 Oncology Testing Market..... 335

7.4.1 Table Oncology – by Country ..... 335

7.4.2 Chart – Oncology Growth ..... 336

7.5 DTC Testing Market ..... 337

7.5.1 Table DTC – by Country ..... 337

7.5.2 Chart – DTC Growth ..... 338

7.6 Other Testing Market ..... 339

7.6.1 Table Other – by Country ..... 339

7.6.2 Chart – Other Growth ..... 340

8. Global Genetic Testing Market by Technology .....341

8.1 PCR Testing Market..... 342

8.1.1 Table PCR – by Country ..... 342

8.1.2 Chart – PCR Growth ..... 343

8.2 NGS Market..... 344

8.2.1 Table NGS – by Country ..... 344

8.2.2 Chart – NGS Growth..... 345

8.3 Cytogenetic Testing Market ..... 346

8.3.1 Table Cytogenetic – by Country ..... 346

8.3.2 Cytogenetic – Predictive Growth ..... 347

8.4 Other Testing Market ..... 348

8.4.1 Table Other – by Country ..... 348

8.4.2 Chart – Other Growth ..... 349

9. The Future of Genetic Testing .....350

Appendices .....351

I. United States Medicare System: 2021 laboratory Fees Schedule..... 351

II Methodology ..... 452

II.1 Authors..... 452

II.2 Sources ..... 452



## Table of Tables

Table 1 Most Common Traditional Genetic Disorders .....	29
Table 2 Lab Spending 2014 to 2024 .....	36
Table 3 Market Players by Type .....	38
Table 4 The Different Types of Genetic Tests .....	43
Table 5 Five Factors Driving Growth .....	54
Table 6 Four Factors Limiting Growth .....	58
Table 7 Key Diagnostic Laboratory Technology Trends .....	62
Table 8 Next Generation Sequencing Technologies – Speed and Cost .....	63
Table 9 Global Market by Country .....	314
Table 10 Global Market by Application.....	316
Table 11 Global Market by Technology .....	322
Table 12 Newborn Segment by Country .....	329
Table 13 NIPT Segment by Country .....	331
Table 14 Predictive Segment by Country .....	333
Table 15 Oncology Segment by Country .....	335
Table 16 DTC Segment by Country .....	337
Table 17 Other Segment by Country .....	339
Table 18 PCR Segment by Country .....	342
Table 19 NGS Segment by Country.....	344
Table 20 Cytogenetic Segment by Country .....	346
Table 21 Other Segment by Country .....	348

Table 22 2021 CLINICAL LAB FEE SCHEDULE..... 351

## Table of Figures

Figure 1 Clinical Lab Spending 2014 to 2024 .....	35
Figure 2 Top Ten Sequencing Companies.....	52
Figure 3 Percentage of World Population Over 65.....	55
Figure 4 Country Market Shares.....	315
Figure 5 Application Share by Year.....	317
Figure 6 Application Segment Growth Rates .....	318
Figure 7 Segment Share Shifts .....	319
Figure 8 Application Segment Share Base Year .....	320
Figure 9 Application Segment Share Final Year .....	321
Figure 10 Technology Share by Year.....	323
Figure 11 Technology Segment Growth Rates.....	324
Figure 12 Technology Segment Share Shifts .....	325
Figure 13 Technology Segment Share Base Year .....	326
Figure 14 Technology Segment Share Final Year .....	327
Figure 15 Newborn vs. Total Market Growth .....	330
Figure 16 NIPT vs. Total Market Growth .....	332
Figure 17 Predictive vs. Total Market Growth .....	334
Figure 18 Oncology vs. Total Market Growth .....	336
Figure 19 DTC vs. Total Market Growth .....	338
Figure 20 Other vs. Total Market Growth .....	340
Figure 21 PCR vs. Total Market Growth .....	343

Figure 22 NGS vs. Total Market Growth..... 345

Figure 23 Cytogenetic vs. Total Market Growth..... 347

Figure 24 Other vs. Total Market Growth ..... 349